Inspire Medical Systems, Inc. (NYSE:INSP) Receives Average Rating of “Hold” from Analysts

Posted by Geri Gentry on May 29th, 2026

Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) has received a consensus recommendation of “Hold” from the twenty research firms that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $81.8421.

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lowered their price objective on Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. UBS Group set a $67.00 target price on Inspire Medical Systems in a report on Friday, February 13th. Piper Sandler lowered Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $85.00 to $55.00 in a report on Tuesday, May 5th. Weiss Ratings lowered Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Finally, Summit Redstone set a $39.00 target price on Inspire Medical Systems in a report on Friday, May 22nd.

Read Our Latest Report on INSP

Institutional Trading of Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of the business. Regal Partners Ltd bought a new stake in Inspire Medical Systems during the third quarter valued at about $7,547,000. Illinois Municipal Retirement Fund lifted its position in shares of Inspire Medical Systems by 262.0% in the third quarter. Illinois Municipal Retirement Fund now owns 25,424 shares of the company’s stock valued at $1,886,000 after acquiring an additional 18,400 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of Inspire Medical Systems by 79.9% in the third quarter. State of New Jersey Common Pension Fund D now owns 23,216 shares of the company’s stock valued at $1,723,000 after acquiring an additional 10,311 shares in the last quarter. Rheos Capital Works Inc. lifted its position in shares of Inspire Medical Systems by 124.0% in the fourth quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock valued at $10,828,000 after acquiring an additional 65,000 shares in the last quarter. Finally, Aberdeen Group plc lifted its position in shares of Inspire Medical Systems by 16.3% in the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock valued at $42,509,000 after acquiring an additional 64,561 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Trading Up 2.2%

Shares of NYSE:INSP opened at $43.16 on Friday. The stock has a fifty day simple moving average of $50.41 and a two-hundred day simple moving average of $75.17. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 9.61, a PEG ratio of 4.36 and a beta of 0.83. Inspire Medical Systems has a 12-month low of $39.61 and a 12-month high of $147.03.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities research analysts predict that Inspire Medical Systems will post 0.91 EPS for the current year.

Inspire Medical Systems Company Profile

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.